Cited by 6,457Health Promotion and Cardiovascular PreventionClinical practice guidelines implementationCardiovascular Health and Risk Factors

2016 European Guidelines on cardiovascular disease prevention in clinical practice

Open access
Piepoli, Massimo F, Hoes, Arno W, Agewall, Stefan, Albus, Christian, Brotons, Carlos, Catapano, Alberico L, Cooney, Marie-Therese, Corrà, Ugo +124 more·2016·European Heart Journal

Abstract

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehw106

Cites

583 of 583 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Healthy lifestyle choices can prevent or delay the onset of high BP and can reduce cardiovascular risk.

    “Healthy lifestyle choices can prevent or delay the onset of high BP and can reduce cardiovascular risk. 46”

    From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [46]

    The hypertension recommendations (pp. 44–46) advise lifestyle measures for people with high-normal BP and say these measures may suffice for some patients with high-normal or grade 1 hypertension. The cost-effective prevention section (p. 6) says healthy lifestyles help prevent cardiovascular disease. Our copy does not specifically say that lifestyle choices prevent or delay the onset of high BP. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Classic calculators for estimating cardiovascular risk that only consider conventional risk factors, such as the Framingham risk score, could underestimate the risk in effectively treated patients.

    “in fact, the classic calculators for estimating cardiovascular risk that only consider conventional risk factors, such as the Framingham risk score, could underestimate the risk in this particular population [8].”

    From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [8]

    Section 2.3.6 (p. 16) says conventional risk charts omit potentially relevant risk factors and that risk modifiers may raise estimated risk. Section 2.3.1 (p. 11) lists Framingham among risk assessment systems. The passages do not establish that these calculators underestimate risk specifically in effectively treated patients. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • Traditional risk factors alone cannot fully explain the high impact of coronary events in effectively treated patients.

    “Traditional risk factors alone cannot fully explain the high impact of coronary events in effectively treated patients; in fact, the classic calculators for estimating cardiovascular risk that only consider conventional risk factors, such as the Framingham risk score, could underestimate the risk in this particular population [8].”

    From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [8]

    Section 2.3.6 (p. 16) says conventional risk factors in risk charts may need additional modifiers, and section 2.1 (p. 7) reports residual cardiovascular risk during treatment. Neither passage establishes that traditional factors fail to explain coronary events specifically in effectively treated patients, or that Framingham underestimates risk in that population. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Intolerance to statins is linked with an elevated risk of cardiovascular disease.

    “Intolerance to statins is linked with an elevated risk of cardiovascular disease [3].”

    From Safety outcomes of statin vs non-statin lipid-lowering interventions in patients with prior statin-associated muscle symptoms: A systematic review and meta-analysis (2025) · cites this paper as [3]

    Section 3a.7.12 (pp. 39–40) says statins reduce cardiovascular morbidity and mortality and discusses alternative treatment for patients intolerant to statins. It does not state that statin intolerance itself is linked to an elevated risk of cardiovascular disease; the claim infers that association from the benefits of statin treatment. (LLM, conf=0.79)

    Experimental — accuracy not yet measured
  • The higher discontinuation rate observed with statins may reflect challenges in patient adherence and could have implications for long-term cardiovascular risk prevention.

    “The higher discontinuation rate observed with statins may reflect challenges in patient adherence and could have implications for long-term cardiovascular risk prevention [3].”

    From Safety outcomes of statin vs non-statin lipid-lowering interventions in patients with prior statin-associated muscle symptoms: A systematic review and meta-analysis (2025) · cites this paper as [3]

    Section 3a.7.12 (p. 39) says statins reduce cardiovascular morbidity and mortality, supporting the concern that continued treatment matters for prevention. The passages found do not report a higher statin discontinuation rate or link such a rate specifically to patient-adherence challenges; the adherence-related material found is a reference list (p. 76). (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

4 retracted

Flagged first, then by citations

2 of the 585 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., Graham, I., Hall, M. S., Hobbs, F. D. R., Løchen, M.-L., Löllgen, H., Marques-Vidal, P., Perk, J., Prescott, E., Redon, J., Richter, D. J., Sattar, N., Smulders, Y., Tiberi, M., van der Worp, H. B., van Dis, I., Verschuren, W. M. M., Binno, S., ESC Scientific Document Group, De Backer, G., Roffi, M., Aboyans, V., Bachl, N., Bueno, H., Carerj, S., Cho, L., Cox, J., De Sutter, J., Egidi, G., Fisher, M., Fitzsimons, D., Franco, O. H., Guenoun, M., Jennings, C., Jug, B., Kirchhof, P., Kotseva, K., Lip, G. Y., Mach, F., Mancia, G., Bermudo, F. M., Mezzani, A., Niessner, A., Ponikowski, P., Rauch, B., Rydén, L., Stauder, A., Turc, G., Wiklund, O., Windecker, S., Zamorano, J. L., Zamorano, J. L., Aboyans, V., Achenbach, S., Agewall, S., Badimon, L., Barón-Esquivias, G., Baumgartner, H., Bax, J. J., Bueno, H., Carerj, S., Dean, V., Erol, Ç., Fitzsimons, D., Gaemperli, O., Kirchhof, P., Kolh, P., Lancellotti, P., Lip, G. Y., Nihoyannopoulos, P., Piepoli, M. F., Ponikowski, P., Roffi, M., Torbicki, A., Vaz Carneiro, A., Windecker, S., Metzler, B., Najafov, R., Stelmashok, V., De Maeyer, C., Dilic, M., Gruev, I., Milicic, D., Vaverkova, H., Gustafsson, I., Attia, I., Duishvili, D., Kostova, N., Ferrières, J., Klimiashvili, Z., Hambrecht, R., Tsioufis, K., Szabados, E., Andersen, K., Vaughan, C., Zafrir, B., Novo, S., Davletov, K., Jashari, F., Kerimkulova, A., Mintale, I., Saade, G., Petrulioniene, Z., Delagardelle, C., Magri, C. J., Rudi, V., Oukerraj, L., Çölkesen, B. E., Schirmer, H., Jankowski, P., dos Reis, R. P., Gherasim, D., Nedogoda, S., Zavatta, M., Giga, V., Filipova, S., Padial, L. R., Kiessling, A., Mach, F., Mahdhaoui, A., Ural, D., Nesukay, E., & Gale, C.
Affiliations
  • International Society of Behavioural Medicine (ISBM)
  • World Organisation of Family Doctors (CN)
  • European Atherosclerosis Society (SE)
  • European Society of Cardiology (FR)
  • International Diabetes Federation (BE)
  • WONCA Europe.
  • International Federation of Sports Medicine (CH)
  • Societie: European Society of Hypertension (ESH)
  • European Association for the Study of Diabetes (DE)
  • Societie: European Stroke Organisation (ESO)
  • Societie: European Heart Network (EHN)
  • Societie: European Society of Cardiology (ESC)
  • European Heart Network (BE)
  • European Society of Hypertension (IT)
  • European Stroke Organisation (CH)
Venue
European Heart Journal
Published
2016-05-23
Volume
37
Issue
29
Pages
2315-2381
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2402599050
Cited by
6,457
References
585
Citations by year
2026: 178 · 2025: 279 · 2024: 398 · 2023: 509 · 2022: 678 · 2021: 996 · 2020: 1017 · 2019: 959 · 2018: 750 · 2017: 570 · 2016: 111 · 2015: 1
FWCI
785.39
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • IRIS (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
National Institute for Health and Care Research (NF-SI-0611-10273, 12/01/52)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
Keywords
cardiovascular disease prevention, secondary prevention, primary prevention, cardiovascular risk management
MeSH terms
Healthy Lifestyle, Multiple Chronic Conditions, Diet, Healthy, Cardiac Rehabilitation, Adult, Age Factors, Aged, Antihypertensive Agents, Cardiovascular Diseases, Cost-Benefit Analysis, Diabetic Angiopathies, Diagnostic Imaging, Health Promotion, Humans, Hyperlipidemias, Hypertension, Middle Aged, Pedigree, Practice Patterns, Physicians', Sex Factors, Socioeconomic Factors, Biomarkers, Exercise, Smoking Cessation, Risk Assessment, General Practice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review